Biogen Pharmachem Industries (531752) Q2 25/26 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half year ended 30 September 2025.

• Financial results reviewed by the Audit Committee and limited review conducted by statutory auditors.

Financial highlights

• Revenue from operations for Q2 FY26 was ₹10.49 lakhs, down from ₹154.28 lakhs in Q1 FY26 and ₹65.05 lakhs in Q2 FY25.

• Net loss for Q2 FY26 was ₹49.15 lakhs, compared to a net profit of ₹134.48 lakhs in Q1 FY26 and a net loss of ₹99.73 lakhs in Q2 FY25.

• For the half year ended 30 September 2025, total income was ₹143.79 lakhs and net profit was ₹85.33 lakhs.

• Basic and diluted EPS for Q2 FY26 stood at (₹0.01), compared to ₹0.01 in Q1 FY26.

Key financial ratios and metrics

• Paid-up equity share capital increased to ₹9,026.03 lakhs as of 30 September 2025 from ₹6,526.03 lakhs a year ago.

• Other equity stood at ₹882.07 lakhs as of 30 September 2025.

• Total assets increased to ₹9,917.53 lakhs as of 30 September 2025 from ₹9,201.77 lakhs as of 31 March 2025.